Ikarian Capital logo

Ikarian Capital

North America, Texas, United States, Dallas

Description

We leverage our co-founder’s medical and financial background to invest both long and short in biotechnology and pharmaceuticals.

Investor Profile

Ikarian Capital has backed more than 9 startups, with 1 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 7 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Post Ipo Equity, Series Unknown, Series A rounds (top funding stages).
  • Majority of deals are located in United States.
  • Strong thematic focus on Biotechnology, Health Care, Therapeutics.

Stage Focus

  • Post Ipo Equity (67%)
  • Series Unknown (22%)
  • Series A (11%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Life Science
  • Pharmaceutical
  • Genetics
  • Medical
  • Clinical Trials
  • Oncology
  • Robotics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Ikarian Capital frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 2
Surveyor Capital
North America, Illinois, United States, Chicago
Co-Investments: 2
Altium Capital
North America, New York, United States, New York
Co-Investments: 3
6C
North America, New York, United States, New York
Co-Investments: 1
Sio Capital Management
North America, New York, United States, New York
Co-Investments: 2
Monashee Investment Management
North America, Massachusetts, United States, Boston
Co-Investments: 2
Sphera Global Healthcare Fund
Asia, Tel Aviv, Israel, Tel Aviv
Co-Investments: 2
Bain Capital Life Sciences
North America, Massachusetts, United States, Boston
Co-Investments: 2
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 2
Fidelity
North America, Massachusetts, United States, Boston
Co-Investments: 2

What are some of recent deals done by Ikarian Capital?

Kazia Therapeutics

Hornsby, New South Wales, Australia

Kazia Therapeutics is an oncology focused biotechnology company.

BiotechnologyClinical TrialsCommercialInnovation ManagementOncologyPharmaceutical
Post Ipo EquityDec 2, 2025
Amount Raised: $32,874,190
NextCure

Beltsville, Maryland, United States

NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs.

BiopharmaBiotechnologyHealth CareOncology
Post Ipo EquityNov 12, 2025
Amount Raised: $21,500,000
Forte Biosciences

Sherman Oaks, California, United States

Forte Biosciences is a biotechnology company that focuses on dermatology.

BiotechnologyHealth CareLife SciencePharmaceutical
Post Ipo EquityNov 20, 2024
Amount Raised: $53,000,000
iBio

Newark, Delaware, United States

iBio is a technology platform that develops pharmaceutical product applications.

BiotechnologyGeneticsRoboticsTherapeutics
Post Ipo EquityMar 26, 2024
Amount Raised: $15,000,000
BioAtla

San Diego, California, United States

BioAtla develops safer, more effective drugs for cancer using a proprietary next-generation antibody discovery and evolution platform.

BiotechnologyHealth CareMedical
Post Ipo EquitySep 29, 2021
Amount Raised: $75,000,000
Renovacor

Philadelphia, Pennsylvania, United States

Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.

BiotechnologyHealth CareLife Science
Post Ipo EquitySep 3, 2021
Amount Raised: $30,000,000
ValenzaBio

Bethesda, Maryland, United States

ValenzaBio is developing safe and effective treatment options for patients with autoimmune and inflammatory diseases.

BiopharmaBiotechnologyHealth CarePharmaceutical
Series AApr 8, 2021
Amount Raised: $79,374,978
X4 Pharmaceuticals

Cambridge, Massachusetts, United States

X4 Pharmaceuticals is a clinical-stage oncology company developing oral small molecule CXCR4 antagonists for the treatment.

BiotechnologyClinical TrialsHealth CareOncologyPharmaceuticalTherapeutics
Post Ipo EquityMar 19, 2021
Amount Raised: $55,000,000
Kineta (Reverse Merger With Yumanity Therapeutics)

Boston, Massachusetts, United States

Yumanity Therapeutics is a biotechnology company that transforms drug discovery for diseases caused by protein misfolding.

BiotechnologyHealth CareTherapeutics
Series UnknownDec 15, 2020
Amount Raised: $33,599,895
Solid Biosciences

Marlborough, Massachusetts, United States

Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.

BiotechnologyGeneticsHealth CareMedical
Post Ipo EquityDec 11, 2020
Amount Raised: $90,000,000

Find More Investors Like Ikarian Capital

Discover similar investors in our database and build your perfect investor list.

Need help with your fundraising strategy?Read our fundraising guides

Ikarian Capital | Pipeseed